Document is current

Article History

Received: 7 December 2024

Accepted: 21 January 2025

First Online: 31 January 2025

Declarations

:

: This study adhered to the ethical guidelines of the Declaration of Helsinki. The Medical Research Ethics Committee of the Academic Hospital Maastricht/Maastricht University determined that the Dutch Medical Research Involving Human Subjects Act was non-applicable to this study (METC azM/UM 2023-0213). All participants provided informed consent for their provided data to be used for research purposes.

: No part of this manuscript, including text and graphics, are copied or published elsewhere in whole or in part.

: This work has previously been presented as poster presentations at the EULAR 2024 Congress (Vienna, Austria, 2024), 14th International Congress on Spondyloarthritides (Ghent, Belgium, 2024) and Dutch Society for Rheumatology Najaarsdagen 2024 (Arnhem, The Netherlands, 2024). Abstracts have been published in Annals of the Rheumatic Diseases (, abstract number: POS0802) and Clinical and Experimental Rheumatology (, abstract number: P101).

: MS has received honoraria from Novartis. CW has received honoraria from Novartis. MvD declares no competing interests. EM has received research grants from AbbVie, Eli Lilly, Novartis, Pfizer and UCB. JV has received honoraria from Eli Lilly. AvT has received research grants from Novartis, Pfizer and UCB, consulting fees from Novartis, Galapagos, Johnson and Johnson and UCB, travel support from AbbVie, and speaker fees from Pfizer and Novartis.